Roberto Jesus Bernardo, MD
Critical Care (Intensivists) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Stanford Health Care · University Healthcare Alliance
Hospitals listed: Good Samaritan Hospital · Indiana University Health · Stanford Health Care. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bernardo’s office to ask if they take your plan before you enroll.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Indiana University HealthIndianapolis, INAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Indiana University Health, which runs 14 hospitalsHome of Indiana University Melvin and Bren Simon Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 2 of 5 · 63% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.199, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.631, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.344, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Indiana University Health
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 8 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.199 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.631 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.344 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.38 (0.74 to 2.02) · 4,418 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.87 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 170.2 (138.94 to 201.46) · 355 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 76 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7 · 112 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.5 · 136 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 325 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.1 · 457 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 628 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 6,141 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.33 (0.16 to 0.5) · 13,186 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.07 to 0.41) · 13,815 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.31 (2.04 to 4.57) · 5,254 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.07 (1.06 to 3.09) · 2,685 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.89 (0.92 to 2.86) · 4,949 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.17 (8.96 to 15.38) · 2,533 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.96 (3.13 to 6.8) · 2,632 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.78 (0.63 to 2.93) · 1,570 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.51 (0.12 to 0.91) · 11,263 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 82 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 1.048 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.372 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.731 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 267 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 17.7 · 728 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -18 · 169 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 9.6 · 408 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 13.9 · 500 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 864 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.9 to 6.5) · 877 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.4 (7.8 to 11.5) · 877 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.4 · 74 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.1 · 100 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.9 · 291 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.8) · 210 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 1,074 cases | No different | Jan 2024 – Dec 2024 |
What patients said (611 patients answered, 15% of those asked)
| Cleanliness | 1 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 1 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 58% |
| Nurses "always" communicated well | 71% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 49% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 60% |
| Staff "always" explained new medications | 63% |
| Nurses "always" explained things so they could understand | 65% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 63% |
| Staff "always" explained possible side effects | 36% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$48,902
Medicare paid this office $48,902 for 145 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 84 | $27,534 | $150 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $8,646 | $86 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,351 | $96 |
| Critical care, each additional 30 minutes | 22 | $2,262 | $78 |
| Insertion of tube in right heart chambers for measurement | 18 | $1,650 | $92 |
See all 7 services
| Critical care, first 30-74 minutes | 84 | $27,534 | $150 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $8,646 | $86 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,351 | $96 |
| Critical care, each additional 30 minutes | 22 | $2,262 | $78 |
| Insertion of tube in right heart chambers for measurement | 18 | $1,650 | $92 |
| Ultrasonic guidance for blood vessel access | 17 | $172 | $10 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 16 | $132 | $8 |
Who their Medicare patients are
145 Original Medicare patients in 2024. Average age 71 · Under 65 17% · 85 and older 12% · Women 49% · Also on Medicaid 23% · Health risk score 2.41. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Heart failure 55% · Coronary heart disease 52% · Chronic kidney disease 51% · COPD 47% · Atrial fibrillation 46% · Diabetes 44% · Depression 39% · Cancer 23% · Stroke 23% · Dementia 15%.
The office billed $163,948, Medicare allowed $63,114 and paid $48,902; for 469 services of 24 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 145 | 469 | 71 | 2.41 | $163,948 | $48,902 |
| 2023 | 132 | 405 | 70 | 3.16 | $273,542 | $46,166 |
| 2022 | 188 | 524 | 68 | 2.57 | $461,256 | $62,062 |
| 2021 | 226 | 665 | 67 | 3.20 | $533,731 | $83,698 |
| 2020 | 93 | 304 | 67 | 2.10 | $214,245 | $34,825 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Critical care, first 30-74 minutes | 66 | $32,142 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $3,920 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $970 | $61 |
| Insertion of tube in right heart chambers for measurement | 11 | $913 | $83 |
| Short return visit (20+ min) | 14 | $634 | $42 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 11 | $98 | $9 |
2022: 9 services
| Critical care, first 30-74 minutes | 114 | $47,072 | $167 |
| Insertion of tube in right heart chambers for measurement | 30 | $3,367 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $2,715 | $78 |
| Short return visit (20+ min) | 15 | $1,301 | $68 |
| Return visit (30+ min) | 11 | $1,159 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $927 | $51 |
| Short return visit (20+ min) | 12 | $612 | $47 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 28 | $308 | $10 |
| Ultrasonic guidance for blood vessel access | 19 | $233 | $11 |
2021: 9 services
| Critical care, first 30-74 minutes | 119 | $63,341 | $169 |
| Long return visit (40+ min) | 24 | $3,721 | $138 |
| Insertion of tube in right heart chambers for measurement | 28 | $2,819 | $101 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $2,513 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $1,925 | $77 |
| Critical care, each additional 30 minutes | 16 | $1,787 | $85 |
| Return visit (30+ min) | 12 | $1,561 | $98 |
| Drug infusion during cardiac catheterization | 13 | $992 | $76 |
| Ultrasonic guidance for blood vessel access | 23 | $248 | $11 |
2020: 6 services
| Critical care, first 30-74 minutes | 51 | $26,288 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $2,042 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,062 | $82 |
| Test to measure rate of airflow | 11 | $141 | $12 |
| Test to examine how well the lungs exchange gases | 11 | $80 | $7 |
| Test to measure largest amount of air breathed in an out | 13 | $45 | $3 |
Medicaid work
$5,857 in 2024
Medicaid paid $5,857 for 72 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 72 | $5,857 |
| 2024 | 72 | 1 | 12 | $5,857 |
| 2023 | 249 | 1 | 24 | $48,918 |
| 2022 | 477 | 1 | 31 | $149,745 |
| 2021 | 273 | 1 | 21 | $63,585 |
| 2020 | 107 | 1 | 25 | $29,036 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 249 | $48,918 |
2022
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 477 | $149,745 |
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 273 | $63,585 |
2020
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 107 | $29,036 |
Drugs they prescribed that Part D paid
$3,005,666
Pharmacies billed $3,005,666 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 539) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
232 generic and 307 brand-name prescriptions · $3,005,666 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Winrevair | 65 | $1,222,768 | $18,812 |
| Opsumit | 54 | $692,307 | $12,821 |
| Orenitram Er | 75 | $529,024 | $7,054 |
| Adempas | 23 | $316,167 | $13,746 |
| Jardiance | 55 | $51,658 | $939 |
See all 13 drugs
| Winrevair | 65 | $1,222,768 | $18,812 |
| Opsumit | 54 | $692,307 | $12,821 |
| Orenitram Er | 75 | $529,024 | $7,054 |
| Adempas | 23 | $316,167 | $13,746 |
| Jardiance | 55 | $51,658 | $939 |
| Ozempic | 14 | $16,102 | $1,150 |
| Sildenafil Citrate | 38 | $3,553 | $93 |
| Spironolactone | 39 | $520 | $13 |
| Torsemide | 15 | $393 | $26 |
| Potassium Chloride | 14 | $296 | $21 |
| Gabapentin | 11 | $198 | $18 |
| Carvedilol | 15 | $192 | $13 |
| Furosemide | 11 | $53 | $5 |
Year by year
| 2024 | 539 | 50 | 0% (0) | 57% | $3,005,666 |
| 2023 | 481 | 58 | None | None | $1,402,795 |
| 2022 | 399 | 37 | None | 36% | $971,364 |
| 2021 | 208 | 29 | 0% (0) | 30% | $439,034 |
| 2020 | 27 | None | 0% (0) | None | $48,690 |
| 2019 | 40 | None | 0% (0) | 80% | $73,936 |
| 2018 | 25 | None | 0% (0) | 60% | $45,527 |
| 2017 | 40 | 16 | 0% (0) | None | $4,838 |
| 2016 | 355 | 49 | None | None | $21,859 |
| 2015 | 264 | 39 | None | None | $12,543 |
| 2014 | 151 | 30 | 7% (11) | 23% | $6,924 |
| 2013 | 57 | 20 | 19% (11) | 19% | $2,240 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Opsumit | 30 | $399,343 | $13,311 |
| Adempas | 13 | $173,777 | $13,367 |
| Ambrisentan | 34 | $170,798 | $5,023 |
| Orenitram Er | 24 | $142,363 | $5,932 |
| Jardiance | 37 | $40,367 | $1,091 |
| Farxiga | 19 | $25,553 | $1,345 |
| Sildenafil Citrate | 23 | $4,175 | $182 |
| Midodrine | 15 | $3,050 | $203 |
| Spironolactone | 66 | $922 | $14 |
| Ondansetron Odt | 15 | $444 | $30 |
| Gabapentin | 19 | $230 | $12 |
| Furosemide | 21 | $53 | $3 |
2022: 14 drugs
| Opsumit | 20 | $251,543 | $12,577 |
| Ambrisentan | 38 | $201,426 | $5,301 |
| Orenitram Er | 13 | $67,735 | $5,210 |
| Farxiga | 27 | $25,589 | $948 |
| Jardiance | 21 | $12,543 | $597 |
| Trelegy Ellipta | 12 | $8,018 | $668 |
| Sildenafil Citrate | 41 | $5,578 | $136 |
| Midodrine | 21 | $4,681 | $223 |
| Tadalafil | 13 | $1,000 | $77 |
| Spironolactone | 27 | $562 | $21 |
| Potassium Chloride | 14 | $476 | $34 |
| Albuterol Sulfate Hfa | 11 | $392 | $36 |
| Gabapentin | 12 | $132 | $11 |
| Furosemide | 16 | $86 | $5 |
2021: 7 drugs
| Adempas | 12 | $141,844 | $11,820 |
| Ambrisentan | 24 | $89,764 | $3,740 |
| Midodrine | 14 | $1,163 | $83 |
| Sildenafil Citrate | 21 | $1,137 | $54 |
| Spironolactone | 14 | $692 | $49 |
| Potassium Chloride | 16 | $595 | $37 |
| Furosemide | 17 | $87 | $5 |
2016: 13 drugs
| Lumigan | 11 | $1,686 | $153 |
| Atorvastatin | 20 | $404 | $20 |
| Omeprazole | 17 | $214 | $13 |
| Metformin | 18 | $184 | $10 |
| Levothyroxine | 14 | $173 | $12 |
| Gabapentin | 16 | $169 | $11 |
| Losartan | 20 | $166 | $8 |
| Simvastatin | 17 | $152 | $9 |
| Amlodipine Besylate | 27 | $142 | $5 |
| Warfarin | 12 | $100 | $8 |
| Lisinopril | 20 | $85 | $4 |
| Montelukast | 12 | $75 | $6 |
| Glipizide | 11 | $43 | $4 |
2015: 5 drugs
| Atorvastatin | 29 | $327 | $11 |
| Levothyroxine | 25 | $203 | $8 |
| Lisinopril | 20 | $69 | $3 |
| Buspirone | 11 | $69 | $6 |
| Amlodipine Besylate | 17 | $44 | $3 |
2014: 2 drugs
| Amlodipine Besylate | 17 | $138 | $8 |
| Omeprazole | 15 | $97 | $6 |
Money from drug and device companies
$46,827 in 2025
| 2025 | 3 | 64 | $38,270 | $46,827 |
| 2024 | 4 | 58 | $11,346 | $31,124 |
| 2023 | 6 | 25 | $5,000 | $7,011 |
| 2022 | 3 | 37 | $7,575 | $10,015 |
| 2021 | 3 | 18 | None | $819 |
| 2020 | 1 | 1 | None | $38 |
| 2019 | 16 | 56 | None | $1,316 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Winrevair | $45,447 | 56 payments
|
| United Therapeutics | Tyvaso | $1,213 | 5 payments
|
| Actelion Pharmaceuticals US | Opsumit | $168 | 3 payments
|
See all 64 published payments
| Merck Sharp & Dohme | Consulting · 2025-12-17 | Winrevair | $930 |
| Merck Sharp & Dohme | Consulting · 2025-11-24 | None | $10,240 |
| Merck Sharp & Dohme | Travel · 2025-11-24 | None | $150 |
| Merck Sharp & Dohme | Meals · 2025-11-15 | Winrevair | $24 |
| Merck Sharp & Dohme | Meals · 2025-11-15 | Winrevair | $48 |
| Merck Sharp & Dohme | Meals · 2025-11-14 | Winrevair | $35 |
| Merck Sharp & Dohme | Travel · 2025-11-14 | Winrevair | $256 |
| Merck Sharp & Dohme | Meals · 2025-11-14 | Winrevair | $48 |
| Merck Sharp & Dohme | Meals · 2025-11-14 | Winrevair | $100 |
| Merck Sharp & Dohme | Travel · 2025-11-13 | Winrevair | $256 |
| Merck Sharp & Dohme | Travel · 2025-11-13 | Winrevair | $221 |
| Merck Sharp & Dohme | Travel · 2025-11-13 | Winrevair | $609 |
| Merck Sharp & Dohme | Travel · 2025-11-13 | Winrevair | $116 |
| Merck Sharp & Dohme | Consulting · 2025-09-29 | Winrevair | $698 |
| United Therapeutics | Meals · 2025-09-29 | Tyvaso | $111 |
| Merck Sharp & Dohme | Paid to speak or teach · 2025-09-10 | Winrevair | $5,760 |
| Merck Sharp & Dohme | Travel · 2025-09-10 | Winrevair | $150 |
| Merck Sharp & Dohme | Travel · 2025-08-27 | Winrevair | $676 |
| Merck Sharp & Dohme | Travel · 2025-08-27 | Winrevair | $967 |
| Merck Sharp & Dohme | Travel · 2025-08-27 | Winrevair | $203 |
| Merck Sharp & Dohme | Meals · 2025-08-27 | Winrevair | $105 |
| Merck Sharp & Dohme | Consulting · 2025-08-25 | Winrevair | $233 |
| Merck Sharp & Dohme | Consulting · 2025-08-25 | Winrevair | $233 |
| Merck Sharp & Dohme | Consulting · 2025-08-06 | None | $233 |
| Merck Sharp & Dohme | Consulting · 2025-07-23 | Winrevair | $465 |
| Merck Sharp & Dohme | Travel · 2025-07-01 | None | $150 |
| Merck Sharp & Dohme | Consulting · 2025-07-01 | None | $5,760 |
| Merck Sharp & Dohme | Travel · 2025-06-20 | Winrevair | $249 |
| Merck Sharp & Dohme | Meals · 2025-06-20 | Winrevair | $60 |
| Merck Sharp & Dohme | Meals · 2025-06-20 | Winrevair | $50 |
| Merck Sharp & Dohme | Meals · 2025-06-20 | Winrevair | $55 |
| Merck Sharp & Dohme | Travel · 2025-06-19 | Winrevair | $887 |
| Merck Sharp & Dohme | Travel · 2025-06-19 | Winrevair | $272 |
| Merck Sharp & Dohme | Meals · 2025-06-19 | Winrevair | $135 |
| Actelion Pharmaceuticals US | Education · 2025-05-29 | Opsumit | $79 |
| United Therapeutics | Meals · 2025-05-20 | None | $50 |
| Actelion Pharmaceuticals US | Meals · 2025-05-18 | None | $60 |
| Merck Sharp & Dohme | Meals · 2025-05-18 | None | $38 |
| United Therapeutics | Meals · 2025-05-16 | None | $96 |
| Merck Sharp & Dohme | Consulting · 2025-05-14 | None | $1,600 |
| Merck Sharp & Dohme | Paid to speak or teach · 2025-03-19 | Winrevair | $5,760 |
| Merck Sharp & Dohme | Travel · 2025-03-13 | Winrevair | $150 |
| Merck Sharp & Dohme | Meals · 2025-03-08 | Winrevair | $65 |
| Merck Sharp & Dohme | Meals · 2025-03-08 | Winrevair | $60 |
| Merck Sharp & Dohme | Meals · 2025-03-08 | Winrevair | $55 |
| Merck Sharp & Dohme | Travel · 2025-03-07 | Winrevair | $229 |
| Merck Sharp & Dohme | Travel · 2025-03-07 | Winrevair | $79 |
| Merck Sharp & Dohme | Travel · 2025-03-07 | Winrevair | $169 |
| Merck Sharp & Dohme | Travel · 2025-03-07 | Winrevair | $641 |
| Merck Sharp & Dohme | Meals · 2025-03-07 | Winrevair | $150 |
| Merck Sharp & Dohme | Travel · 2025-02-12 | None | $150 |
| Merck Sharp & Dohme | Consulting · 2025-02-12 | None | $5,490 |
| Merck Sharp & Dohme | Travel · 2025-02-03 | Winrevair | $26 |
| Merck Sharp & Dohme | Meals · 2025-02-02 | Winrevair | $26 |
| Merck Sharp & Dohme | Travel · 2025-02-02 | Winrevair | $129 |
| Merck Sharp & Dohme | Meals · 2025-02-02 | Winrevair | $17 |
| Merck Sharp & Dohme | Travel · 2025-02-01 | Winrevair | $20 |
| Merck Sharp & Dohme | Meals · 2025-02-01 | Winrevair | $10 |
| Merck Sharp & Dohme | Travel · 2025-02-01 | Winrevair | $129 |
| Merck Sharp & Dohme | Meals · 2025-02-01 | Winrevair | $48 |
| United Therapeutics | Meals · 2025-02-01 | None | $85 |
| Merck Sharp & Dohme | Meals · 2025-01-31 | None | $33 |
| Actelion Pharmaceuticals US | Meals · 2025-01-30 | Opsumit | $29 |
| United Therapeutics | Consulting · 2025-01-02 | None | $870 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $31,124
| Actelion Pharmaceuticals US | Uptravi | $18,790 | 12 payments
|
| United Therapeutics | Tyvaso | $9,442 | 23 payments
|
| Merck Sharp & Dohme | Winrevair | $2,850 | 22 payments
|
| Sandoz | Treprostinil | $41 | 1 payment
|
2023: $7,011
| United Therapeutics | Tyvaso | $6,205 | 15 payments
|
| Actelion Pharmaceuticals US | Uptravi | $415 | 5 payments
|
| Bayer Healthcare Pharmaceuticals | Adempas | $200 | 1 payment
|
| Merck Sharp & Dohme | None | $142 | 2 payments
|
| Sandoz | Treprostinil | $26 | 1 payment
|
| Novo Nordisk | Ozempic | $22 | 1 payment
|
2022: $10,015
| Actelion Pharmaceuticals US | Uptravi | $9,118 | 11 payments
|
| United Therapeutics | Tyvaso | $753 | 25 payments
|
| Merck Sharp & Dohme | None | $145 | 1 payment
|
2021: $819
| United Therapeutics | Tyvaso | $585 | 16 payments
|
| Actelion Pharmaceuticals US | Uptravi | $119 | 1 payment
|
| Mentor Worldwide | Mentor Memorygel Resterilizable Gel Sizer | $114 | 1 payment
|
2020: $38
| United Therapeutics | None | $38 | 1 payment
|
2019: $1,316
| Actelion Pharmaceuticals US | Uptravi | $223 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $194 | 7 payments
|
| GlaxoSmithKline | Nucala | $187 | 13 payments
|
| Allergan | Avycaz | $170 | 7 payments
|
| Gilead Sciences | None | $131 | 6 payments
|
| United Therapeutics | Orenitram | $99 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Adempas | $69 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $58 | 3 payments
|
| Ekos | Ekosonic | $37 | 1 payment
|
| Portola Pharmaceuticals | Andexxa | $34 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $26 | 2 payments
|
| Relypsa | Veltassa | $20 | 1 payment
|
| Chiesi USA | Cleviprex | $19 | 1 payment
|
| Edwards Lifesciences | Flotrac Sensor | $18 | 1 payment
|
| Jazz Pharmaceuticals | Xyrem | $16 | 1 payment
|
| Insmed | Arikayce | $15 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme LLC · A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-Ph Due To Heart Failure With Preserved Ejection Fraction Hfpef · 2024 | Their institution | $126,046 |
| United Therapeutics Corporation · 2024 | Their institution | $100,000 |
| Merck Sharp & Dohme LLC · A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-Ph Due To Heart Failure With Preserved Ejection F · 2025 | Their institution | $90,060 |
| United Therapeutics Corporation · A Phase 4, Prospective, Multicenter, Single-Arm Study of A Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy To Reverse Right Ventricular Remodeling in Patients With Pulmonary Arterial Hypertension: Artisan (Afterload Reduction To Improve Right Ventricular Structure and Function) · 2024 | Their institution | $75,728 |
| United Therapeutics Corporation · A Phase 4, Prospective, Multicenter, Single-Arm Study of A Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy To Reverse Right Ventricular Remodeling in Patients With Pulmonary Arterial Hypertension: Artisan (Afterload Reduction To Improve Right Ventricular Structure and Function) · 2025 | Their institution | $32,507 |
| Merck Sharp & Dohme LLC · A Phase 2, Multicenter, Single-Blinded, Randomized Study To Evaluate the Pharmacokinetics and Safety of Sotatercept Mk-7962 Administered Using Either A Weight-Based Or Weight-Banded Approach in Participants With Pulmonary Arterial Hypertension Pah on · 2025 | Their institution | $21,167 |
| Merck Sharp & Dohme LLC · A Phase 2, Multicenter, Single-Blinded, Randomized Study To Evaluate the Pharmacokinetics and Safety of Sotatercept Mk-7962 Administered Using Either A Weight-Based Or Weight-Banded Approach in Participants With Pulmonary Arterial Hypertension Pah on Standard of Care · 2024 | Their institution | $20,860 |
| United Therapeutics Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ralinepag To Evaluate Safety and Effects on Exercise Capacity Assessed By Cpet in Subjects With Who Group 1 Pulmonary Hypertension Who Recently Initiated Therapy · 2022 | Their institution | $10,500 |
| United Therapeutics Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ralinepag To Evaluate Safety and Effects on Exercise Capacity Assessed By Cpet in Subjects With Who Group 1 Pulmonary Hypertension Who Recently Initiated Therapy · 2023 | Their institution | $3,303 |
| Merck Sharp & Dohme LLC · A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-Ph Due To Heart Failure With Preserved Ejection Fraction Hfpef · 2023 | Their institution | $1,742 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 71.7 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1063853109
- Licence
- AZ R74169, IN 01089650A
- Group
- Stanford Health Care · University Healthcare Alliance
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- IN 300074949
- Taxonomy
- Federal specialty code 207RC0200X (207RC0200X); Internal medicine (207R00000X); Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2013-07-16
- NPI last updated
- 2025-09-02
- NPI record certified
- 2025-09-02
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 725 Welch Rd, Palo Alto, CA, 94304
This office lists an electronic records connection.